Our top pick for
Building a portfolio
Aravive, Inc is a biotechnology business based in the US. Aravive shares (ARAV) are listed on the NASDAQ and all prices are listed in US Dollars. Aravive employs 16 staff and has a market cap (total outstanding shares value) of USD$99.4 million.
|Latest market close||USD$6.01|
|52-week range||USD$3.34 - USD$14.94|
|50-day moving average||USD$5.8879|
|200-day moving average||USD$7.0838|
|Wall St. target price||USD$19.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-6.653|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||2.56%|
|1 month (2020-12-23)||-4.60%|
|3 months (2020-10-22)||16.25%|
|6 months (2020-07-22)||-42.16%|
|1 year (2020-01-22)||-44.56%|
|2 years (2019-01-22)||66.48%|
|3 years (2018-01-22)||182.82%|
|5 years (2016-01-22)||14.04|
|Gross profit TTM||USD$-8,083,000|
|Return on assets TTM||-26.36%|
|Return on equity TTM||-63.63%|
|Market capitalisation||USD$99.4 million|
TTM: trailing 12 months
There are currently 685,173 Aravive shares held short by investors – that's known as Aravive's "short interest". This figure is 3.7% down from 711,538 last month.
There are a few different ways that this level of interest in shorting Aravive shares can be evaluated.
Aravive's "short interest ratio" (SIR) is the quantity of Aravive shares currently shorted divided by the average quantity of Aravive shares traded daily (recently around 239570.97902098). Aravive's SIR currently stands at 2.86. In other words for every 100,000 Aravive shares traded daily on the market, roughly 2860 shares are currently held short.
However Aravive's short interest can also be evaluated against the total number of Aravive shares, or, against the total number of tradable Aravive shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aravive's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aravive shares in existence, roughly 40 shares are currently held short) or 0.0566% of the tradable shares (for every 100,000 tradable Aravive shares, roughly 57 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aravive.
Find out more about how you can short Aravive stock.
We're not expecting Aravive to pay a dividend over the next 12 months.
Aravive's shares were split on a 1:6 basis on 16 October 2018. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aravive shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Aravive shares which in turn could have impacted Aravive's share price.
Over the last 12 months, Aravive's shares have ranged in value from as little as $3.34 up to $14.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aravive's is 3.2079. This would suggest that Aravive's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.